Steady Revenue Growth for Johnson & Johnson vs. Stagnant Revenue for Novo Nordisk
JNJ Johnson & Johnson
$278.70 -1.36%
View chart & analysis → - 1Johnson & Johnson possesses 28 products and platforms that each generate more than $1 billion in annual revenue.
- 2Novo Nordisk is struggling to find sales momentum as competitors catch up with their own weight-loss products.
- 3While Johnson & Johnson shows a trend of steady quarterly revenue growth, Novo Nordisk's revenue remains mostly stagnant except for a single surge.
So what's the key point?
Johnson & Johnson's revenue is growing steadily, but Novo Nordisk's revenue is staying nearly the same. Novo Nordisk is having difficulty increasing sales as competitors release weight-loss products.
Source The Motley Fool +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.